News
(Reuters) -Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, the companies said on Monday. Regeneron said it will comply ...
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results